You can eat, enjoy the experience, and make reasonable food choices without the compound fighting you every step of the way
Both outcomes are clinically meaningful, but they illustrate why BMI at treatment initiation shapes expectations about results
Systematic review of 26 RCTs, 15,491 participants
In a nutshell, semglutide is a GLP-1 receptor agonist, originally developed for type 2 diabetes
Since going public in 2021 through a $1.6 billion SPAC deal, its grown into a major telehealth company, expanding into mental health and dermatology although Hims continues to post videos about, well: On May 20, Hims announced it would also sell its own version of GLP-1 weight loss injections like Ozempic and Wegovy
Tilt the vial slightly as you rotate it